Industry views sought on EMA genomic biomarker consultation in drug development
This article was originally published in Scrip
Drug companies have until 25 November 2011 to respond to a reflection paper from the European Medicines Agency that represents the preliminary thinking of the agency on the role of genomic biomarkers in the development and testing of human medicinal products.
You may also be interested in...
The UK Medicines and Healthcare products Regulatory Agency is developing a series of guidance documents on general points to consider when planning a trial to generate real-world evidence. The first document in this series focuses on prospective randomized trials.
With still no guarantee of what kind of access the UK will have to the EU’s all-important Article 57 database after the Brexit transition period ends, drug companies will have to provide key information about their pharmacovigilance systems directly to the UK medicines regulator.
More than a year after UK health technology assessment body NICE started offering scientific advice on designing patient preference studies, only two companies have sought guidance. NICE has also contributed to related projects that it hopes will increase the relevance of such studies in the context of an HTA appraisal.